A Phase 4 interventional study of Cefazolin 2 g Infusion and Cefazolin 2 GM Injection in Surgical Site Infection (SSI), sponsored by Helwan University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-24.
Sponsored by Helwan University · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing cefazolin in Surgical Wound Infection — 4 open to participants now, 5 under way, 2 of them phase 3. Cefazolin · Surgical Wound Infection.
Among the 18 studies testing cefazolin in Surgical Wound Infection, this one is the 13th largest by planned enrollment, is one of 3 that started in 2026, is one of 8 in phase 4, and was the 16th registered.
747 studies on the registry are indexed under Surgical Wound Infection; 152 are open to participants now.
Browse Surgical Wound Infection studies →4 of the 18 studies testing cefazolin in Surgical Wound Infection are open now, in 6 countries. Recruiting first, the newest first:
Monash University · Sites in United States, Australia, Canada and 2 more countries
Ages 18+
University Hospital, Clermont-Ferrand · Sites in France
Ages 18+
Helwan University
Ages 18+
By country, each count listing its studies:
Cefazolin: first FDA approval 1973 (ANCEF). What it is approved for, and how studies give it, is on its page →
Of the 85 Surgical Wound Infection studies recruiting now, 62 (73%) set no upper age limit and 16 (19%) stop at 75 or younger; 12 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 200 across 583 interventional studies indexed under Surgical Wound Infection.
Median enrollment 180 across the 18 interventional studies. Of the 11 that completed or were terminated, 2 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 18 has an industry lead sponsor. The 10 most frequent:
Helwan University is the lead sponsor of 70 studies on the registry; 15 are open to participants now.
Helwan University has 2 studies filed under Surgical Wound Infection — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing cefazolin in Surgical Wound Infection, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A randomized controlled trial on adults who underwent coronary artery bypass grafting (CABG) surgery. To evaluate the effectiveness of intraoperative continuous infusion (CI) of cefazolin compared with intermittent (INT) cefazolin administration in preventing surgical site infection in the CABG population.
Eligible patients will be randomized using a block design into 2 groups: intervention and control. The intervention group will use continuous infusion of cefazolin (CI), while the control group will follow the traditional presurgical prophylaxis protocol of intermittent cefazolin doses (INT).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Cefazolin 2 g Infusion
Drug: Cefazolin 2 GM Injection
To evaluate the effectiveness of intraoperative continuous infusion (CI) of cefazolin compared with intermittent (INT) cefazolin administration in preventing SSIs in a CABG (coronary artery bypass grafting) population.
To evaluate the effectiveness of intermittent (INT) cefazolin administration in preventing SSIs in a CABG (coronary artery bypass grafting) population.
Incidence of SSI
Time frame: Within 3 months after surgery
No study locations are listed for this record.
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Jul 2026; primary completion for Sep 2026, 2 months later.
Of 45 non-industry phase 4 interventional studies under Surgical Wound Infection, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 51. This study's planned 2 months is below that.
Counting every sponsor, half of 47 studies reached it within 30 months; a quarter within 16 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cefazolin
Helwan University